Thirteen Finalists Chosen for Boehringer Ingelheim and Ashoka Changemakers "Making More Health" Competition

Boehringer IngelheimBoehringer Ingelheim and Ashoka Changemakers announced that thirteen finalists have been selected in the first Boehringer Ingelheim Making More Health competition. The online competition is part of a three-year global initiative to identify and support the most promising solutions to challenging health problems around the world. The public is now invited to vote to determine the competition's three winners, who will each receive a $10,000 (US) cash prize to help further their idea.

The finalists, selected from more than 470 entries received, represent the most innovative and promising solutions from around the globe that are transforming the field of health. Finalists were selected by the competition's panel of expert judges, which included Aman Bhandari of the U.S. Department of Health and Human Services, Carol A. Dahl, executive director of The Lemelson Foundation, and Andreas Barner, Chairman of the Board of Managing Directors for Boehringer Ingelheim.

The goal of the Making More Health competition is to identify and support innovations with the potential to shape the future of the health sector for the benefit of individuals, families, and communities. Entries addressed a broad range of health and healthcare challenges from prevention and lifestyle, to detection and treatment. The 13 finalists represent the most innovative solutions for improving health systems in these areas.

"The Making More Health competition reflects Boehringer Ingelheim’s commitment to supporting leadership and innovation in healthcare and to improving health for individuals, families, and communities," said Jean Scheftsik de Szolnok, Vice-President Southern Europe for Boehringer Ingelheim. "By identifying and supporting new approaches to healthcare delivery we are helping to ensure a sustainable future in which good health for everyone is possible."

The finalists in the first Making More Health competition are:

  • Affordable, Quality Health Care and Services for the Underprivileged, Pakistan
  • ColaLife: Piggybacking Simple Medicines on Cola Supply Chains, to Save Lives in Underserved Rural areas in Africa, Zambia
  • Cool2Care - Tackling Disability by Connecting Young Curers with Families in Need, United Kingdom
  • eDOTS: Demanding Reliable Results from Tuberculosis Treatment, India
  • E HealthPoint Transforming Rural Healthcare, India
  • A Life-Saving Diagnosis: Sample Transport, Reducing the Time Delay in Monitoring and Diagnosing HIV and TB, Lesotho
  • miraclefeet: Preventing Unnecessary Disability Caused by Untreated Clubfoot Around the World, United States
  • Pathways to Wellness: Integrating Refugee Health and Well-Being, United States
  • RevoLOOtionary: Developing Rural Markets for Sanitation, Cambodia
  • SMS Now! A Life Depends on It, India
  • Saúde Criança: Holistic Health Solutions for Families in Favelas, Brazil
  • Sustainable Sanitation in Urban Slums: The Path to Permanently Reducing Sanitation-Related Disease, Kenya
  • Unite For Sight, Ghana

The public can vote at www.changemakers.com/morehealth and from the Changemakers Facebook page between November 9 and November 30, 2011. Winners will be announced on December 7, 2011.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.In 2010, Boehringer Ingelheim posted net sales of 12.6 billion euro while spending almost 24% of net sales in its largest business segment Prescription Medicines on research and development.

About Ashoka Changemakers
Ashoka Changemakers is an online community of action that connects social entrepreneurs around the globe to share ideas, inspire, and mentor each other. Through its online collaborative competitions and open-source process, Changemakers.com is one of the world's most robust spaces for launching, discussing, and scaling-up ideas to solve the world's most pressing social problems. Changemakers builds on Ashoka's three-decade history and vision for an "Everyone a Changemaker" world by creating a place where the best ideas in social innovation can be shared, refined, and funded.

Most Popular Now

Study finds lack of racial diversity in cancer dru…

New research published in JAMA Oncology has found a lack of racial and ethnic diversity in clinical trials for cancer drugs. The study - conducted by researchers from UBC...

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Roche's first FDA-approved tumour-agnostic medicin…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek™ (entrectinib) for the treatment of adults with R...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

Amgen and Allergan announce positive top-line resu…

Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...